Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women

Exclusion Criteria

• •Use of estrogen or hormone replacement therapy
• •Use of parathormone or parathormone fragments, calcitonin, aluminum supplements, within 12 months prior to first dose.
• •Use of bisphosphonates and strontium ranelate
• •Cancer or history of malignancy of any organ system
• •Any radiation therapy to the skeleton.
• •Any known clinically significant disease affecting calcium metabolism. Any history of metabolic disorders including Paget's disease, osteogenesis imperfecta, or osteomalacia.
• •History or clinical evidence of any impairment of thyroid function